Investor directory

OSF Ventures

OSF Ventures is a strategic investment arm that focuses on financially and operationally supporting innovations in healthcare to enhance patient outcomes, improve experiences, and reduce costs. Operating under the OSF HealthCare family in Illinois and Michigan, OSF Ventures values collaboration, curiosity, and risk-taking to champion compassionate care for all. OSF HealthCare, established in 1877, is a non-profit organization providing a wide range of clinical services, including cancer care, diabetes treatment, emergency services, and heart care. With a commitment to justice, compassion, integrity, teamwork, employee well-being, and stewardship, OSF HealthCare serves over 2.5 million individuals across central and northern Illinois and northern Michigan through a network of acute care facilities, primary care physicians, and specialized providers. Through strategic investments and partnerships, OSF Ventures contributes to transforming healthcare and improving the lives of those they serve.

Focus

Scale StageHealth DiagnosticsSeries ASeries BEarly VentureShow more
http://www.osfhealthcare.org
http://www.osfmedicalgroup.org
https://crunchbase.com/organization/osf
https://crunchbase.com/organization/osf-healthcare
https://crunchbase.com/organization/osf-healthcare-3c5a
https://crunchbase.com/organization/osf-ventures
https://facebook.com/osfhealthcare
https://linkedin.com/company/973835
https://linkedin.com/company/osf-healthcare
https://twitter.com/osfhealthcare
https://twitter.com/osfventures
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=331059722
https://www.privateequityinternational.com/database/#/profile?id=18073

Mathew Hanley

Vice President of Finance

Amanda Lowry

Vice President Controller

Stan Lynall

Vice President, Venture Investments

Stanley Lynall

VP of Venture Investments

Diane McGrew

President, Treasurer and Director

Liridon Rrushaj

Director, Venture Investments

Mayank Taneja

Director, Venture Investments

Garrett Vygantas

Managing Director, Venture Investments

58 past transactions

Level Ex

Private Placement in 2018
Level Ex is a developer of professional medical video games designed for physicians to capture the challenges of practicing medicine. The company uses state-of-the-art video game technology and cognitive neuroscience to capture the challenges of practicing medicine, allowing physicians to keep up-to-speed on rare and challenging cases, new medical devices and drug therapies.

Pieces

Series A in 2016
Our journey started at Parkland Health & Hospital System, Dallas’ large safety-net hospital system, when our founder, Ruben Amarasingham, MD, began developing predictive models to prevent readmissions. His work resulted in the creation of the non-profit research institute, PCCI, which has received more than $50 million in scientific funding. Pieces grew out of PCCI as a nimble hub of innovation and problem-solving for organizations around the globe.

Euphrates Vascular

Merger/Acquisition in 2016
As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

Insight Rx, Inc.

Private Placement in 2019
Insight Rx, Inc. develops and operates a cloud-based platform that applies the principles of quantitative pharmacology and machine learning to improve patient care. It offers InsightRX, an online platform that guides treatment decisions at individual level where drug concentration and biomarker data are collected over-time to learn about the patient response and optimize treatment; and at population level where data is collected in larger patient populations/in infrequently encountered patient populations. The company’s platform is also used to leverage clinically validated pharmacokinetic models, patient physiology, pharmacogenomics, drug concentrations, and biomarkers to optimize dosing; leverage disease-based pharmacodynamics models to inform treatment decision making; and learn about patient populations, and provide patient benchmarking and dose/response metrics. Insight Rx, Inc. was founded in 2015 and is based in San Francisco, California.

Huddle Up

Series A in 2021
DotCom Therapy specializes in providing speech therapy, occupational therapy, and mental health services via computer, tablet, or smartphone. They hand-match students, patients, and clients with our therapists who provide the highest quality therapy in a live, online, face-to-face setting. It offers speech, occupational and mental health therapy, educational audiology, case management, and literacy services. The company was founded in 2015 and is based in Madison, Wisconsin, United States.

AVIA

Private Placement in 2019
AVIA helps hospitals and health systems to identify, select and deploy the best emerging IT-enabled solutions to drive growth, improve operating efficiency and compete on value. We facilitate collaboration between providers and entrepreneurs to accelerate the impact and to mitigate the risk of innovation adoption. Solutions of greatest interest to our members address needs related to population health via clinical data insights, care model redesign, patient engagement and operational efficiency.

Socially Determined

Series A in 2019
Socially Determined is the social risk analytics company for organizations committed to addressing the Social Determinants of Health (SDOH). Its flagship platform SocialScape® quantifies social risk factors and analyzes the impact of these factors on health and business metrics, and its team of social risk experts provides advisory services to translate these insights into actionable solutions with measurable benefits.

VIDA

Series C in 2020
VIDA modernizes lung and respiratory care, empowering healthcare organizations and physicians to improve patient outcomes, streamline care coordination and drive efficiencies through a comprehensive approach, proven quality, and clinical leadership. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and now, COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. Learn more at vidalung.ai.

Renovia

Series C in 2021
Renovia produces medical devices that seek to alleviate incontinence in women. It offers diagnostic and therapeutic devices for women with pelvic floor disorders. Marc Beer, Ramon Iglesias, and Yolanda Lorié founded Renovia in 2016. Its headquarters is in Boston in Massachusetts.

eXo Imaging, Inc.

Private Placement in 2019
eXo Imaging, Inc. develops an ultrasound platform and artificial intelligence (AI) for imaging and therapeutic applications. Its ultrasound platform includes a transducer technology that combines nano materials and advanced signal processing for imaging the whole body. The company’s ultrasound platform also includes a micro-machined ultrasound technology (pMUT) that marries nanoscale piezoelectric materials with semiconductor capabilities. The company was founded in 2015 and is based in Redwood City, California.

InsightRx

Venture Round in 2017
InsightRX is a software platform that incorporates the principles of quantitative pharmacology and machine learning to provide an individualized understanding of a patient’s response to treatment. It delivers its technology in the form of easy-to-use clinical decision support tools at the point-of-care to help guide treatment decision-making. The platform guides treatment decisions at both the individual level and the population level. InsightRX controls clinically validated pharmacokinetic models, patient physiology, pharmacogenomics, drug concentrations, and biomarkers to optimize dosing. It combines real-time patient data and machine learning to understand individual patient pharmacology and inform dose optimization. The platform also leverages disease-based pharmacodynamics models to inform treatment decision making. InsightRX was launched in 2015 by Ron Keizer, Sirj Goswami, and Ranvir Mangat. It is operated from San Francisco, California.

Regroup Therapy

Series B in 2018
Regroup provides telemedicine solutions to eradicate mental healthcare shortages across the USA. The company's services protect the privacy of patients and the confidentiality of personal health information with the help of an end-to-end encryption thus improving access to mental health care, enabling patients to overcome geographic distances, restrictions on their mobility, transportation difficulties and the time and cost burdens associated with traveling to see a healthcare professional in person.

SilverCloud Health

Series B in 2020
Silvercloud Health Limited develops online platform for therapeutic solutions via tailored clinical programs. It provides online health and wellness solutions. The company’s SilverCloud platform gives users the ability to offer therapies to various people who need professional support quickly. The company serves to healthcare, medical, and pharmaceutical sectors. Silvercloud Health Limited was incorporated in 2012 and is based in Dublin, Ireland with additional offices in London, United Kingdom and Boston, Massachusetts.

Huddle Up

Private Placement in 2020
DotCom Therapy specializes in providing speech therapy, occupational therapy, and mental health services via computer, tablet, or smartphone. They hand-match students, patients, and clients with our therapists who provide the highest quality therapy in a live, online, face-to-face setting. It offers speech, occupational and mental health therapy, educational audiology, case management, and literacy services. The company was founded in 2015 and is based in Madison, Wisconsin, United States.

PhotoniCare

Private Placement in 2020
PhotoniCare, Inc., a medical device company, develops a handheld diagnostic tool that enables physicians to diagnose middle ear infections. It offers TOMi Scope, a device that uses near-infrared light waves to provide 3D views beyond the eardrum into the middle ear, and studies the accuracy and validity of optical coherence tomography imaging. The company’s device uses an advanced light-based technology to see through the eardrum. PhotoniCare, Inc. was founded in 2013 and is based in Champaign, Illinois.

Socially Determined

Private Placement in 2019
Socially Determined is the social risk analytics company for organizations committed to addressing the Social Determinants of Health (SDOH). Its flagship platform SocialScape® quantifies social risk factors and analyzes the impact of these factors on health and business metrics, and its team of social risk experts provides advisory services to translate these insights into actionable solutions with measurable benefits.

Regroup Therapy

Series A in 2017
Regroup provides telemedicine solutions to eradicate mental healthcare shortages across the USA. The company's services protect the privacy of patients and the confidentiality of personal health information with the help of an end-to-end encryption thus improving access to mental health care, enabling patients to overcome geographic distances, restrictions on their mobility, transportation difficulties and the time and cost burdens associated with traveling to see a healthcare professional in person.

Paradigm Diagnostics, Inc.

Private Placement in 2016
Paradigm Diagnostics, Inc. provides diagnostics and biomarker driven clinical trial services for cancer patients. The company offers PCDx test that provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and inventory of relevant clinical trials, as well as assesses clinically-actionable genomic variations in cancer, including mutations, copy number variations, mRNA expression, and protein expression. It also offers BioPharma services, which include personalized clinical trial assays, biorepository consultation, molecular services, nucleic acid isolation, and laser capture enrichment, as well as bio specimen collection, storage, processing, and analysis services. The company was founded in 2012 and is based in Phoenix, Arizona. As of March 3, 2020, Paradigm Diagnostics, Inc. operates as a subsidiary of Exact Sciences Corporation.

Exo

Series B in 2019
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.

Paradigm Diagnostics

Series B in 2019
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.

Renovia

Series B in 2018
Renovia produces medical devices that seek to alleviate incontinence in women. It offers diagnostic and therapeutic devices for women with pelvic floor disorders. Marc Beer, Ramon Iglesias, and Yolanda Lorié founded Renovia in 2016. Its headquarters is in Boston in Massachusetts.

Endotronix

Private Placement in 2016
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

410 Medical

Series A in 2019
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

Health Scholars

Series B in 2020
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

Health Catalyst

Series E in 2016
Catalyst is solving healthcare data warehouse issues for some of the nation’s top health systems. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. Catalyst helps organize, normalize, and link the data from all different systems. And they make it searchable by all users, even the non-technical, by using rich metadata capabilities.

VIDA

Private Placement in 2020
VIDA modernizes lung and respiratory care, empowering healthcare organizations and physicians to improve patient outcomes, streamline care coordination and drive efficiencies through a comprehensive approach, proven quality, and clinical leadership. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and now, COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. Learn more at vidalung.ai.

IDx

Series B in 2022
Digital Diagnostics is an AI diagnostics company that transforms the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician-scientists, the company is focused on developing clinically-aligned autonomous algorithms that detect disease in medical images. By enabling diagnostic assessment in primary care settings, it aims to increase patient access to high-quality, affordable disease detection. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. It is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. Digital Diagnostics was formerly known as IDx.

Cardiosense

Series A in 2022
There are clear physiological changes preceding acute cardiac events, but detection has traditionally required invasive catheters and implants. Cardiosense is a small, lightweight patch capable of capturing this same information in any setting. By analyzing physiological trends, Cardiosense detects early signs of cardiac decline before any symptoms appear. This allows care teams to prioritize at-risk patients, implement therapeutic interventions, and prevent hospitalizations.

Socially Determined

Series B in 2022
Socially Determined is the social risk analytics company for organizations committed to addressing the Social Determinants of Health (SDOH). Its flagship platform SocialScape® quantifies social risk factors and analyzes the impact of these factors on health and business metrics, and its team of social risk experts provides advisory services to translate these insights into actionable solutions with measurable benefits.

Epitel

Series A in 2022
Epitel is building a brain health management platform backed by powerful data analytics, starting with seizure detection.

CancerIQ

Series B in 2022
CancerIQ’s technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at canceriq.com.

Endotronix

Series D in 2018
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Endotronix

Series C in 2016
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Inflammatix

Series D in 2021
Inflammatix, Inc., a molecular diagnostics company, develops rapid tests that read the immune system to resolve clinical and public health challenges. It focuses on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers. The company also builds a host response-based diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions. Inflammatix, Inc. was founded in 2016 and is based in Burlingame, California.

Renovia

Private Placement in 2018
Renovia produces medical devices that seek to alleviate incontinence in women. It offers diagnostic and therapeutic devices for women with pelvic floor disorders. Marc Beer, Ramon Iglesias, and Yolanda Lorié founded Renovia in 2016. Its headquarters is in Boston in Massachusetts.

Huddle Up

Series A in 2020
DotCom Therapy specializes in providing speech therapy, occupational therapy, and mental health services via computer, tablet, or smartphone. They hand-match students, patients, and clients with our therapists who provide the highest quality therapy in a live, online, face-to-face setting. It offers speech, occupational and mental health therapy, educational audiology, case management, and literacy services. The company was founded in 2015 and is based in Madison, Wisconsin, United States.

PatientWisdom, LLC

Venture Round in 2017
PatientWisdom, LLC develops and operates a platform that collects, curates, segments, and shares patient stories to improve the experience and delivery of health and care. It serves patients and families, healthcare providers, researchers and educators, and manufacturers and payers. The company was incorporated in 2015 and is based in New Haven, Connecticut.

Current Health

Series B in 2021
Current Health Limited manufactures wearable healthcare devices to measure patient’s vitals and to alert in case of emergency. The product identifies unwell patients to make early decisions. The product can be used to measure oxygen saturation, respiration rate, pulse rate, temperature, motion & activity, and posture. Current Health Limited was formerly known as Snap40 Limited and changed its name to Current Health Limited in December 2018. Current Health Limited was founded in 2014 and is based in Edinburgh, United Kingdom.

Gauss Surgical

Series C in 2018
Gauss Surgical is a med-tech company that develops a vision-based platform for accurate and real-time measurement of surgical blood loss. They develop beautiful applications for iOS backed by sophisticated algorithms and a robust, HIPAA-compliant technical stack to enable real-time monitoring during surgery. The company was incorporated in 2011 and is headquartered in Menlo Park, California.

PhotoniCare

Series A in 2020
PhotoniCare, Inc., a medical device company, develops a handheld diagnostic tool that enables physicians to diagnose middle ear infections. It offers TOMi Scope, a device that uses near-infrared light waves to provide 3D views beyond the eardrum into the middle ear, and studies the accuracy and validity of optical coherence tomography imaging. The company’s device uses an advanced light-based technology to see through the eardrum. PhotoniCare, Inc. was founded in 2013 and is based in Champaign, Illinois.

Level Ex

Corporate Round in 2018
Level Ex is a developer of professional medical video games designed for physicians to capture the challenges of practicing medicine. The company uses state-of-the-art video game technology and cognitive neuroscience to capture the challenges of practicing medicine, allowing physicians to keep up-to-speed on rare and challenging cases, new medical devices and drug therapies.

AVIA

Series C in 2016
AVIA helps hospitals and health systems to identify, select and deploy the best emerging IT-enabled solutions to drive growth, improve operating efficiency and compete on value. We facilitate collaboration between providers and entrepreneurs to accelerate the impact and to mitigate the risk of innovation adoption. Solutions of greatest interest to our members address needs related to population health via clinical data insights, care model redesign, patient engagement and operational efficiency.

BrightWater Medical

Series A in 2016
BrightWater Medical is a mid-stage medical device company uniquely positioned to significantly impact the treatment of ureteral blockages by interventional radiologists. The company was founded by Dr. Bob Smouse, Associate Professor of Radiology & Surgery, University of Illinois College of Medicine. Dr. Smouse is a leading interventional radiologist, clinician, academic and entrepreneur, with more than 20 years of experience in interventional radiology, endovascular surgery and clinical research.

Endotronix

Private Placement in 2018
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

CareSignal

Venture Round in 2020
CareSignal provides an accessible remote patient monitoring platform that improves payer and provider performance in value-based care by engaging and identifying rising-risk patients. Care teams receive real-time alerts enabling real-time prioritization and outreach, and patients respond to evidence-based questions via text messages or phone calls.

Epharmix

Private Placement in 2020
Epharmix, Inc. develops clinically validated and condition-specific communication tools for health care industry. Its products provide digital interventions that are built per condition and patient population to maintain patient-physician engagement, collect clinical data over time automatically, and algorithmically alert health care providers to provide chronic care management for the patients. Epharmix, Inc. was founded in 2015 and is based in Saint Louis, Missouri.

eXo Imaging, Inc.

Private Placement in 2020
eXo Imaging, Inc. develops an ultrasound platform and artificial intelligence (AI) for imaging and therapeutic applications. Its ultrasound platform includes a transducer technology that combines nano materials and advanced signal processing for imaging the whole body. The company’s ultrasound platform also includes a micro-machined ultrasound technology (pMUT) that marries nanoscale piezoelectric materials with semiconductor capabilities. The company was founded in 2015 and is based in Redwood City, California.

Pieces

Series B in 2020
Our journey started at Parkland Health & Hospital System, Dallas’ large safety-net hospital system, when our founder, Ruben Amarasingham, MD, began developing predictive models to prevent readmissions. His work resulted in the creation of the non-profit research institute, PCCI, which has received more than $50 million in scientific funding. Pieces grew out of PCCI as a nimble hub of innovation and problem-solving for organizations around the globe.

410 Medical, Inc.

Private Placement in 2019
410 Medical, Inc. operates in the healthcare industry. The company was incorporated in 2013 and is based in Chapel Hill, North Carolina.

SilverCloud Health

Private Placement in 2020
Silvercloud Health Limited develops online platform for therapeutic solutions via tailored clinical programs. It provides online health and wellness solutions. The company’s SilverCloud platform gives users the ability to offer therapies to various people who need professional support quickly. The company serves to healthcare, medical, and pharmaceutical sectors. Silvercloud Health Limited was incorporated in 2012 and is based in Dublin, Ireland with additional offices in London, United Kingdom and Boston, Massachusetts.

Euphrates Vascular

Venture Round in 2016
As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

InsightRx

Series A in 2019
InsightRX is a software platform that incorporates the principles of quantitative pharmacology and machine learning to provide an individualized understanding of a patient’s response to treatment. It delivers its technology in the form of easy-to-use clinical decision support tools at the point-of-care to help guide treatment decision-making. The platform guides treatment decisions at both the individual level and the population level. InsightRX controls clinically validated pharmacokinetic models, patient physiology, pharmacogenomics, drug concentrations, and biomarkers to optimize dosing. It combines real-time patient data and machine learning to understand individual patient pharmacology and inform dose optimization. The platform also leverages disease-based pharmacodynamics models to inform treatment decision making. InsightRX was launched in 2015 by Ron Keizer, Sirj Goswami, and Ranvir Mangat. It is operated from San Francisco, California.

Huddle Up

Series C in 2024
DotCom Therapy specializes in providing speech therapy, occupational therapy, and mental health services via computer, tablet, or smartphone. They hand-match students, patients, and clients with our therapists who provide the highest quality therapy in a live, online, face-to-face setting. It offers speech, occupational and mental health therapy, educational audiology, case management, and literacy services. The company was founded in 2015 and is based in Madison, Wisconsin, United States.

410 Medical

Series B in 2023
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

410 Medical

Series B in 2022
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.